Literature DB >> 7705667

Cytoreductive surgery in advanced epithelial cancer of the ovary: the impact of aortic and pelvic lymphadenectomy.

N M Spirtos1, G M Gross, J L Freddo, S C Ballon.   

Abstract

Beginning in July 1988, a planned program was undertaken to assess the role of aortic and pelvic lymphadenectomy in patients with advanced epithelial cancer of the ovary (Stages IIIa-IVa) undergoing cytoreductive surgery. Our intent was to perform a complete aortic and pelvic lymphadenectomy in all patients in whom we could surgically remove all intra- or retroperitoneal disease measuring 1 cm or greater. Accordingly, 56/77 patients (73%) underwent complete aortic and pelvic lymphadenectomy. The remaining 21/77 patients (27%) did not, either because the lymphadenectomy would not have impacted on the patient's cytoreductive status or because intraoperative conditions precluded it. Positive lymph nodes were found in 36/56 patients (64%). Of these, 23/36 (64%) were macroscopically positive, and if left in situ would have affected the patient's cytoreductive status. Thirteen of 36 (36%) were positive microscopically. Reassessment laparotomy was performed in 44/56 (79%) of the patients having had a lymphadenectomy and is correlated to disease status. Median follow-up is 30 months (range 2-64 months). Survival analysis reveals: 10/20 patients (50%) with negative lymph nodes; 6/13 patients (46%) with microscopically positive lymph nodes; 10/23 patients (43%) with macroscopically positive, but surgically removed lymph nodes; and only 2/21 patients (10%) with residual disease measuring at least 1 cm in diameter are alive without evidence of disease. These preliminary findings suggest that the removal of macroscopically negative lymph nodes offers little benefit to the patient with advanced epithelial cancer and minimal residual (less than 1 cm) disease. However, the concept of cytoreductive surgery, whether it be intra- or retroperitoneal, appears to be validated by the fact that the patients undergoing removal of macroscopically positive lymph nodes have approximately the same chance of survival as those with microscopically positive and/or negative lymph nodes.

Entities:  

Mesh:

Year:  1995        PMID: 7705667     DOI: 10.1006/gyno.1995.1061

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  8 in total

Review 1.  Management of retroperitoneal lymph nodes in the treatment of ovarian cancer.

Authors:  Kimio Ushijima
Journal:  Int J Clin Oncol       Date:  2007-06-27       Impact factor: 3.402

2.  Clinical impact of systematic pelvic and para-aortic lymphadenectomy for pT1 and pT2 ovarian cancer: a retrospective survey by the Sankai Gynecology Study Group.

Authors:  Takafumi Oshita; Hiroaki Itamochi; Ryuichiro Nishimura; Fumitaka Numa; Kazuhiro Takehara; Masamichi Hiura; Hirotoshi Tanimoto; Jun Noma; Ryoji Hayase; Akihiro Murakami; Hideo Fujimoto; Yasunobu Kanamori; Fuminori Kitada; Keiji Shitsukawa; Makoto Nagaji; Yukihisa Minagawa; Michihisa Fujiwara; Junzo Kigawa
Journal:  Int J Clin Oncol       Date:  2012-10-17       Impact factor: 3.402

3.  What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study.

Authors:  Bunja J Rungruang; Austin Miller; Thomas C Krivak; Neil S Horowitz; Noah Rodriguez; Chad A Hamilton; Floor J Backes; Linda F Carson; Michael Friedlander; David G Mutch; Michael J Goodheart; Krishnansu S Tewari; Robert M Wenham; Michael A Bookman; G Larry Maxwell; Scott D Richard
Journal:  Cancer       Date:  2016-11-16       Impact factor: 6.860

4.  Stage IIIC epithelial ovarian cancer classified solely by lymph node metastasis has a more favorable prognosis than other types of stage IIIC epithelial ovarian cancer.

Authors:  Su-Jin Baek; Jeong-Yeol Park; Dae-Yeon Kim; Jong-Hyeok Kim; Yong-Man Kim; Young-Tak Kim; Joo-Hyun Nam
Journal:  J Gynecol Oncol       Date:  2008-12-29       Impact factor: 4.401

5.  Efficient delivery of Notch1 siRNA to SKOV3 cells by cationic cholesterol derivative-based liposome.

Authors:  Yun-Chun Zhao; Li Zhang; Shi-Sen Feng; Lu Hong; Hai-Li Zheng; Li-Li Chen; Xiao-Ling Zheng; Yi-Qing Ye; Meng-Dan Zhao; Wen-Xi Wang; Cai-Hong Zheng
Journal:  Int J Nanomedicine       Date:  2016-10-20

6.  The relationship between retroperitoneal lymphadenectomy and survival in advanced ovarian cancer patients.

Authors:  Chenyan Fang; Yingli Zhang; Lingqin Zhao; Xi Chen; Liang Xia; Ping Zhang
Journal:  BMC Cancer       Date:  2020-07-13       Impact factor: 4.430

7.  Systematic lymphadenectomy in ovarian cancer at second-look surgery: a randomised clinical trial.

Authors:  T Dell' Anna; M Signorelli; P Benedetti-Panici; A Maggioni; R Fossati; R Fruscio; R Milani; L Bocciolone; A Buda; C Mangioni; G Scambia; R Angioli; E Campagnutta; R Grassi; F Landoni
Journal:  Br J Cancer       Date:  2012-08-02       Impact factor: 7.640

8.  The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13918 patients.

Authors:  J K Chan; R Urban; J M Hu; J Y Shin; A Husain; N N Teng; J S Berek; K Osann; D S Kapp
Journal:  Br J Cancer       Date:  2007-05-22       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.